EXEL
Exelixis, Inc.
NASDAQ · Healthcare · Biotechnology · US
$59.01
−0.20%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
15.9x
EV/EBITDA
13.4x
Market Cap
$14.62B
MomentumView details →
1D Return
−0.20%
YTD Return
+34.69%
RSI (14)
64.6
ValuationView details →
P/E (Fwd)
15.9x
EV/EBITDA
13.4x
Market Cap
$14.62B
RSI (14)
64.6
MomentumView details →
1D Return
−0.20%
YTD Return
+34.69%
SummaryUpdated Jul 1, 2026
Exelixis, Inc. (NASDAQ:EXEL) is an oncology-focused biotechnology company founded in 1994 and headquartered in Alameda, California. Originally incorporated as Exelixis Pharmaceuticals, Inc., the company changed its name to Exelixis, Inc. in February 2000 and went public that same year. What began as a drug discovery company has evolved into a leading commercial-stage biotechnology firm specializing in cancer treatments. Today, Exelixis has successfully transitioned from a research-focused organization to a profitable company with multiple approved cancer therapies and a robust pipeline of experimental treatments targeting various solid tumors.
Similar companies
Latest newsMore news →
Handa Biotechnology announced that its new anticancer drug HND-039 (Omcazio capsules) received final approval from the US FDA, allowing it to enter the US market, with the originator's patent expiring in late August and a citizen petition dismissed.7h agoThe U.S. Court of Appeals for the Federal Circuit affirmed a key portion of the 2024 District Court judgment in favor of Exelixis in its patent litigation against MSN Laboratories, upholding the decision that three patents covering Exelixis' product are valid and infringed.4d ago